Telo Genomics Corp

Price Chart

Risk-Adjusted Performance

Telo Genomics Corp (TDSGF) Price Performance

Telo Genomics Corp (TDSGF) trades on United States in USD. The company is classified in the Healthcare sector under the Diagnostics & Research industry. The stock currently trades at $0.04, down 1.50% from the previous close.

Over the past year, TDSGF has traded between a low of $0.03 and a high of $0.08. The stock has lost 46.0% over this period. It is currently 50.8% below its 52-week high.

Telo Genomics Corp has a market capitalization of $4.02M.

About Telo Genomics Corp

Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company's TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability, identify specific disease mechanisms, predict disease risks, and determine effective treatments. Its lead product is TeloView-SMM (Smoldering Multiple Myeloma) for SMM patients with a high risk of transition to multiple myeloma (MM). The company also develops TeloView NDMM, which predicts newly diagnosed MM patients who may relapse on first-line therapy; TeloMRD-D, which identifies and enumerates MRD cells in post-transplant patients; and TeloViewNG-MRD (Minimal Residual Disease) Profiling for genomic instability profiling of MRD-detected cells in post-transplant patients. It has a collaboration agreement with the Mayo Clinic. Telo Genomics Corp. is headquartered in Toronto, Canada.

Compare Telo Genomics Corp

Side-by-side comparison against top Healthcare peers.